We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Advancing Cancer Therapy With Exosome Isolation and Detection Kits

Advancing Cancer Therapy With Exosome Isolation and Detection Kits content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

AMSBIO have introduced a new range of proprietary reagents designed for researchers investigating targeted cancer therapy.

Targeted cancer therapy represents a promising new cancer treatment, one which delivers drugs in specific carriers and interferes with the specific target molecules that play a critical role in tumor growth and progression. Exosomes expressing specific surface markers (among them CD81, CD63, and CD9) have been found to play roles in cancer progression and tumorigenesis as a transporter of miRNA. As a delivery system, they can therefore potentially be used as a specific carrier of immunotherapy/chemotherapy and cancer vaccines, as can be seen in a growing number of biotech companies, such as Evox Therapeutics developing exosome-based therapies.

The new column-based exosome isolation kit from AMSBIO works to isolate intact exosomes from both serum and cell-conditioned media.  Exosome detection ELISA kits quantify exosome levels in the fractions as well as in samples such as culture media and sera. In addition, AMSBIO also provides monoclonal antibodies against common exosome markers and immune checkpoint ligands for immunostaining, ELISA, or flow cytometry.